Program
ALXN1920
A development code.
Its studies are mostly in Glomerulonephritis, Membranous, led by AstraZeneca.
Furthest: phase 2, since Aug 28, 20252 company-led studies, 1 open or runningNext primary completion: Jul 2, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 21 open or running | phase 2since Aug 28, 2025 | Feb 21, 2023 | Jul 2, 2027phase 2 · NCT07157787 |
- Named in AstraZeneca’s own pipeline as
ALXN1920
, phase 2, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 21, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT05751642 · 48 enrolled · New Zealand
- Aug 28, 2025Phase 2 study in Primary Membranous NephropathyNCT07157787 · 30 planned · United States, Argentina, Australia and more
Ahead
- Jul 2, 2027Primary completion: phase 2 study in Primary Membranous NephropathyNCT07157787
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07157787Primary Membranous Nephropathy · United States, Argentina, Australia and more | 2 | Recruiting | Jul 2, 2027 | 30 |
| NCT05751642Healthy Participants · New Zealand | 1 | Completed | Dec 4, 2023 | 48 |
How it is read
Names in the registry
- “ALXN1920”, 4 entries
Codes read as this program: ALXN1920.
Conditions, from the studies’ own filings
- Glomerulonephritis, Membranous, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.